Kearny Venture Partners

Kearny Venture Partners, established in 2000 and headquartered in San Francisco, is a venture capital firm dedicated to the healthcare sector. With over $330 million in capital under management, the firm invests in early-stage healthcare companies, focusing on innovative products and therapies across pharmaceuticals, biotechnology, life sciences, and healthcare devices. Kearny Venture Partners aims to capitalize on significant unmet needs and emerging opportunities in healthcare, supporting entrepreneurs who develop safe and effective solutions.

Caley Castelein

Co-Founder and Partner

Anupam Dalal

Managing Director

Jim Shapiro

Managing Director

Richard Spalding JD

Partner

27 past transactions

Elektrofi

Series C in 2024
Elektrofi is a preclinical-stage company based in Boston, Massachusetts, focused on revolutionizing drug delivery to enhance patient experiences. Founded in 2016, Elektrofi specializes in a formulation system capable of processing a broad spectrum of therapeutic molecules, including large and complex proteins such as monoclonal antibodies, bispecifics, and fusion proteins. The company's technology aims to improve subcutaneous administration, enabling drug manufacturers to create innovative therapies that offer patients greater control over how they receive life-changing medicines.

Cybin

Series B in 2020
Cybin is a biopharmaceutical company dedicated to advancing research and development in psychedelic and medicinal mushrooms. It focuses on creating safe and effective therapeutics for mental health issues, with an emphasis on psilocybin-based products. The company is actively launching these products in jurisdictions where they are permitted and is engaged in clinical studies across North America and other regions. Through strategic partnerships with academic and institutional entities, Cybin seeks to develop novel compounds and delivery mechanisms, aiming to provide innovative treatments for various psychiatric and neurological conditions.

Aerpio Pharmaceuticals

Venture Round in 2017
Aerpio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cincinnati, Ohio, focused on developing innovative compounds for the treatment of ocular diseases and diabetic complications. The company's lead candidate, razuprotafib, is a small molecule activator of the Tie2 pathway that has completed a Phase IIb clinical trial for diabetic retinopathy. Additionally, Aerpio is advancing ARP-1536, a humanized monoclonal antibody in preclinical development for diabetic vascular complications, and GB004, a selective stabilizer of hypoxia-inducible factor-1 alpha, currently undergoing a Phase 1b trial for inflammatory bowel disease. Furthermore, the company is developing a bispecific antibody for the treatment of wet age-related macular degeneration and diabetic macular edema. Aerpio has also partnered with Quantum Leap Healthcare Collaborative to evaluate razuprotafib's potential in treating acute respiratory distress syndrome in COVID-19 patients. Founded in 2011, Aerpio Pharmaceuticals aims for rapid development of its promising therapies.

ViewRay

Post in 2017
ViewRay, Inc. is a medical technology company that specializes in designing, manufacturing, and marketing advanced radiation therapy systems for cancer treatment. Its flagship product, MRIdian, is a magnetic resonance image-guided radiation therapy system that simultaneously images and treats cancer patients. By integrating MRI technology with radiation delivery and proprietary software, MRIdian enhances the precision of radiation therapy. It can accurately locate and target soft-tissue tumors while minimizing exposure to surrounding healthy tissue. This capability allows clinicians to treat patients who might not have been suitable candidates for traditional radiation therapy, ultimately leading to improved safety and effectiveness in treatment outcomes. Headquartered in Oakwood, Ohio, ViewRay serves a diverse range of healthcare institutions, including university research hospitals, community hospitals, and freestanding cancer centers, and operates both domestically and internationally. The company was founded in 2004.

ViewRay

Post in 2016
ViewRay, Inc. is a medical technology company that specializes in designing, manufacturing, and marketing advanced radiation therapy systems for cancer treatment. Its flagship product, MRIdian, is a magnetic resonance image-guided radiation therapy system that simultaneously images and treats cancer patients. By integrating MRI technology with radiation delivery and proprietary software, MRIdian enhances the precision of radiation therapy. It can accurately locate and target soft-tissue tumors while minimizing exposure to surrounding healthy tissue. This capability allows clinicians to treat patients who might not have been suitable candidates for traditional radiation therapy, ultimately leading to improved safety and effectiveness in treatment outcomes. Headquartered in Oakwood, Ohio, ViewRay serves a diverse range of healthcare institutions, including university research hospitals, community hospitals, and freestanding cancer centers, and operates both domestically and internationally. The company was founded in 2004.

ViewRay

Post in 2015
ViewRay, Inc. is a medical technology company that specializes in designing, manufacturing, and marketing advanced radiation therapy systems for cancer treatment. Its flagship product, MRIdian, is a magnetic resonance image-guided radiation therapy system that simultaneously images and treats cancer patients. By integrating MRI technology with radiation delivery and proprietary software, MRIdian enhances the precision of radiation therapy. It can accurately locate and target soft-tissue tumors while minimizing exposure to surrounding healthy tissue. This capability allows clinicians to treat patients who might not have been suitable candidates for traditional radiation therapy, ultimately leading to improved safety and effectiveness in treatment outcomes. Headquartered in Oakwood, Ohio, ViewRay serves a diverse range of healthcare institutions, including university research hospitals, community hospitals, and freestanding cancer centers, and operates both domestically and internationally. The company was founded in 2004.

Aerpio Pharmaceuticals

Series C in 2014
Aerpio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cincinnati, Ohio, focused on developing innovative compounds for the treatment of ocular diseases and diabetic complications. The company's lead candidate, razuprotafib, is a small molecule activator of the Tie2 pathway that has completed a Phase IIb clinical trial for diabetic retinopathy. Additionally, Aerpio is advancing ARP-1536, a humanized monoclonal antibody in preclinical development for diabetic vascular complications, and GB004, a selective stabilizer of hypoxia-inducible factor-1 alpha, currently undergoing a Phase 1b trial for inflammatory bowel disease. Furthermore, the company is developing a bispecific antibody for the treatment of wet age-related macular degeneration and diabetic macular edema. Aerpio has also partnered with Quantum Leap Healthcare Collaborative to evaluate razuprotafib's potential in treating acute respiratory distress syndrome in COVID-19 patients. Founded in 2011, Aerpio Pharmaceuticals aims for rapid development of its promising therapies.

ViewRay

Venture Round in 2013
ViewRay, Inc. is a medical technology company that specializes in designing, manufacturing, and marketing advanced radiation therapy systems for cancer treatment. Its flagship product, MRIdian, is a magnetic resonance image-guided radiation therapy system that simultaneously images and treats cancer patients. By integrating MRI technology with radiation delivery and proprietary software, MRIdian enhances the precision of radiation therapy. It can accurately locate and target soft-tissue tumors while minimizing exposure to surrounding healthy tissue. This capability allows clinicians to treat patients who might not have been suitable candidates for traditional radiation therapy, ultimately leading to improved safety and effectiveness in treatment outcomes. Headquartered in Oakwood, Ohio, ViewRay serves a diverse range of healthcare institutions, including university research hospitals, community hospitals, and freestanding cancer centers, and operates both domestically and internationally. The company was founded in 2004.

TriVascular

Series E in 2013
TriVascular Technologies, Inc. is a medical device company focused on developing and commercializing innovative technologies for the minimally invasive treatment of abdominal aortic aneurysms (AAA) and thoracic aortic aneurysms (TAA). Based in Santa Rosa, California, TriVascular specializes in endovascular grafts and self-expanding stent grafts, including the Ovation and Ovation Prime Stent Grafts, which utilize polymer-filled sealing rings to enhance procedural efficacy. The company’s products are designed to improve patient outcomes by reducing mortality, morbidity, and costs associated with traditional open surgical repair. TriVascular markets its technologies through direct sales in the United States and select European countries, as well as through distributors in other regions. Founded in 2007, TriVascular operates as a subsidiary of Endologix Inc. and emphasizes addressing unmet clinical needs while fostering a supportive work environment for its employees.

Aerpio Pharmaceuticals

Series A in 2013
Aerpio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cincinnati, Ohio, focused on developing innovative compounds for the treatment of ocular diseases and diabetic complications. The company's lead candidate, razuprotafib, is a small molecule activator of the Tie2 pathway that has completed a Phase IIb clinical trial for diabetic retinopathy. Additionally, Aerpio is advancing ARP-1536, a humanized monoclonal antibody in preclinical development for diabetic vascular complications, and GB004, a selective stabilizer of hypoxia-inducible factor-1 alpha, currently undergoing a Phase 1b trial for inflammatory bowel disease. Furthermore, the company is developing a bispecific antibody for the treatment of wet age-related macular degeneration and diabetic macular edema. Aerpio has also partnered with Quantum Leap Healthcare Collaborative to evaluate razuprotafib's potential in treating acute respiratory distress syndrome in COVID-19 patients. Founded in 2011, Aerpio Pharmaceuticals aims for rapid development of its promising therapies.

Boreal Genomics

Series C in 2013
Boreal Genomics Inc. is a biotechnology company that specializes in the development and marketing of technologies for the blood-based detection and monitoring of circulating tumor DNA. Founded in 2007 and headquartered in Los Altos, California, with an additional office in Vancouver, Canada, the company focuses on improving cancer patient care through innovative diagnostic tools and research applications. Its OnTarget platform enables highly sensitive detection and quantification of tumor mutations in plasma, facilitating accurate tumor profiling and real-time monitoring of tumor evolution. Boreal Genomics also offers the Aurora tool, which purifies and concentrates nucleic acids from various sample types, enhancing the accuracy of sequencing in liquid biopsy applications. These technologies aim to guide therapy selection, improve the efficiency of clinical trials, and accelerate drug development processes.

Akebia Therapeutics

Series C in 2013
Akebia Therapeutics, Inc. is a biopharmaceutical company dedicated to the development and commercialization of therapeutics for kidney diseases. The company's primary product is Auryxia, a ferric citrate formulation approved for managing serum phosphorus levels in adult patients with chronic kidney disease, both on dialysis and those not requiring dialysis, as well as for treating iron deficiency anemia. Additionally, Akebia is advancing vadadustat, an oral therapy that is currently in Phase III clinical development for treating anemia associated with chronic kidney disease. The company has established collaboration agreements with Otsuka Pharmaceutical Co. Ltd. and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in various global markets, alongside a research and licensing agreement with Janssen Pharmaceutica NV for related compounds. Founded in 2007, Akebia Therapeutics is headquartered in Cambridge, Massachusetts.

ViewRay

Venture Round in 2013
ViewRay, Inc. is a medical technology company that specializes in designing, manufacturing, and marketing advanced radiation therapy systems for cancer treatment. Its flagship product, MRIdian, is a magnetic resonance image-guided radiation therapy system that simultaneously images and treats cancer patients. By integrating MRI technology with radiation delivery and proprietary software, MRIdian enhances the precision of radiation therapy. It can accurately locate and target soft-tissue tumors while minimizing exposure to surrounding healthy tissue. This capability allows clinicians to treat patients who might not have been suitable candidates for traditional radiation therapy, ultimately leading to improved safety and effectiveness in treatment outcomes. Headquartered in Oakwood, Ohio, ViewRay serves a diverse range of healthcare institutions, including university research hospitals, community hospitals, and freestanding cancer centers, and operates both domestically and internationally. The company was founded in 2004.

TriVascular

Series D in 2012
TriVascular Technologies, Inc. is a medical device company focused on developing and commercializing innovative technologies for the minimally invasive treatment of abdominal aortic aneurysms (AAA) and thoracic aortic aneurysms (TAA). Based in Santa Rosa, California, TriVascular specializes in endovascular grafts and self-expanding stent grafts, including the Ovation and Ovation Prime Stent Grafts, which utilize polymer-filled sealing rings to enhance procedural efficacy. The company’s products are designed to improve patient outcomes by reducing mortality, morbidity, and costs associated with traditional open surgical repair. TriVascular markets its technologies through direct sales in the United States and select European countries, as well as through distributors in other regions. Founded in 2007, TriVascular operates as a subsidiary of Endologix Inc. and emphasizes addressing unmet clinical needs while fostering a supportive work environment for its employees.

ViewRay

Series C in 2012
ViewRay, Inc. is a medical technology company that specializes in designing, manufacturing, and marketing advanced radiation therapy systems for cancer treatment. Its flagship product, MRIdian, is a magnetic resonance image-guided radiation therapy system that simultaneously images and treats cancer patients. By integrating MRI technology with radiation delivery and proprietary software, MRIdian enhances the precision of radiation therapy. It can accurately locate and target soft-tissue tumors while minimizing exposure to surrounding healthy tissue. This capability allows clinicians to treat patients who might not have been suitable candidates for traditional radiation therapy, ultimately leading to improved safety and effectiveness in treatment outcomes. Headquartered in Oakwood, Ohio, ViewRay serves a diverse range of healthcare institutions, including university research hospitals, community hospitals, and freestanding cancer centers, and operates both domestically and internationally. The company was founded in 2004.

ViewRay

Debt Financing in 2011
ViewRay, Inc. is a medical technology company that specializes in designing, manufacturing, and marketing advanced radiation therapy systems for cancer treatment. Its flagship product, MRIdian, is a magnetic resonance image-guided radiation therapy system that simultaneously images and treats cancer patients. By integrating MRI technology with radiation delivery and proprietary software, MRIdian enhances the precision of radiation therapy. It can accurately locate and target soft-tissue tumors while minimizing exposure to surrounding healthy tissue. This capability allows clinicians to treat patients who might not have been suitable candidates for traditional radiation therapy, ultimately leading to improved safety and effectiveness in treatment outcomes. Headquartered in Oakwood, Ohio, ViewRay serves a diverse range of healthcare institutions, including university research hospitals, community hospitals, and freestanding cancer centers, and operates both domestically and internationally. The company was founded in 2004.

Akebia Therapeutics

Series B in 2011
Akebia Therapeutics, Inc. is a biopharmaceutical company dedicated to the development and commercialization of therapeutics for kidney diseases. The company's primary product is Auryxia, a ferric citrate formulation approved for managing serum phosphorus levels in adult patients with chronic kidney disease, both on dialysis and those not requiring dialysis, as well as for treating iron deficiency anemia. Additionally, Akebia is advancing vadadustat, an oral therapy that is currently in Phase III clinical development for treating anemia associated with chronic kidney disease. The company has established collaboration agreements with Otsuka Pharmaceutical Co. Ltd. and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in various global markets, alongside a research and licensing agreement with Janssen Pharmaceutica NV for related compounds. Founded in 2007, Akebia Therapeutics is headquartered in Cambridge, Massachusetts.

NextWave Pharmaceuticals

Series C in 2011
NextWave Pharmaceuticals is a Cupertino, California-based pharmaceutical company that specializes in the development and commercialization of innovative products utilizing proprietary drug delivery technology. The company is primarily focused on creating once-daily liquid medications aimed at treating attention deficit/hyperactivity disorder (ADHD). By leveraging its unique drug delivery systems, NextWave Pharmaceuticals enables healthcare providers to effectively address various disorders related to the central nervous system, enhancing treatment options for patients.

ViewRay

Series C in 2010
ViewRay, Inc. is a medical technology company that specializes in designing, manufacturing, and marketing advanced radiation therapy systems for cancer treatment. Its flagship product, MRIdian, is a magnetic resonance image-guided radiation therapy system that simultaneously images and treats cancer patients. By integrating MRI technology with radiation delivery and proprietary software, MRIdian enhances the precision of radiation therapy. It can accurately locate and target soft-tissue tumors while minimizing exposure to surrounding healthy tissue. This capability allows clinicians to treat patients who might not have been suitable candidates for traditional radiation therapy, ultimately leading to improved safety and effectiveness in treatment outcomes. Headquartered in Oakwood, Ohio, ViewRay serves a diverse range of healthcare institutions, including university research hospitals, community hospitals, and freestanding cancer centers, and operates both domestically and internationally. The company was founded in 2004.

TriVascular

Series C in 2010
TriVascular Technologies, Inc. is a medical device company focused on developing and commercializing innovative technologies for the minimally invasive treatment of abdominal aortic aneurysms (AAA) and thoracic aortic aneurysms (TAA). Based in Santa Rosa, California, TriVascular specializes in endovascular grafts and self-expanding stent grafts, including the Ovation and Ovation Prime Stent Grafts, which utilize polymer-filled sealing rings to enhance procedural efficacy. The company’s products are designed to improve patient outcomes by reducing mortality, morbidity, and costs associated with traditional open surgical repair. TriVascular markets its technologies through direct sales in the United States and select European countries, as well as through distributors in other regions. Founded in 2007, TriVascular operates as a subsidiary of Endologix Inc. and emphasizes addressing unmet clinical needs while fostering a supportive work environment for its employees.

Baxano

Series C in 2010
Baxano, Inc. is a medical device company specializing in the development of minimally invasive tools aimed at restoring spine function while preserving healthy tissue. Founded in 2005 and based in San Jose, California, the company offers the iO-Flex System, designed to target and decompress bone and soft tissue in the foramen, lateral recess, and central canal, catering to patients with varying degrees of spinal stenosis. Baxano's product lineup includes the Neuro Check device, which enables surgeons to verify safe positioning against the bone while ensuring the nerve is adequately protected. Additionally, it features the MicroBlade Shaver, an instrument for removing impinging bone and ligament, along with essential accessories such as guidewires, probes, and distal handles.

TriVascular

Series B in 2009
TriVascular Technologies, Inc. is a medical device company focused on developing and commercializing innovative technologies for the minimally invasive treatment of abdominal aortic aneurysms (AAA) and thoracic aortic aneurysms (TAA). Based in Santa Rosa, California, TriVascular specializes in endovascular grafts and self-expanding stent grafts, including the Ovation and Ovation Prime Stent Grafts, which utilize polymer-filled sealing rings to enhance procedural efficacy. The company’s products are designed to improve patient outcomes by reducing mortality, morbidity, and costs associated with traditional open surgical repair. TriVascular markets its technologies through direct sales in the United States and select European countries, as well as through distributors in other regions. Founded in 2007, TriVascular operates as a subsidiary of Endologix Inc. and emphasizes addressing unmet clinical needs while fostering a supportive work environment for its employees.

Akebia Therapeutics

Series A in 2009
Akebia Therapeutics, Inc. is a biopharmaceutical company dedicated to the development and commercialization of therapeutics for kidney diseases. The company's primary product is Auryxia, a ferric citrate formulation approved for managing serum phosphorus levels in adult patients with chronic kidney disease, both on dialysis and those not requiring dialysis, as well as for treating iron deficiency anemia. Additionally, Akebia is advancing vadadustat, an oral therapy that is currently in Phase III clinical development for treating anemia associated with chronic kidney disease. The company has established collaboration agreements with Otsuka Pharmaceutical Co. Ltd. and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in various global markets, alongside a research and licensing agreement with Janssen Pharmaceutica NV for related compounds. Founded in 2007, Akebia Therapeutics is headquartered in Cambridge, Massachusetts.

Baxano

Series B in 2008
Baxano, Inc. is a medical device company specializing in the development of minimally invasive tools aimed at restoring spine function while preserving healthy tissue. Founded in 2005 and based in San Jose, California, the company offers the iO-Flex System, designed to target and decompress bone and soft tissue in the foramen, lateral recess, and central canal, catering to patients with varying degrees of spinal stenosis. Baxano's product lineup includes the Neuro Check device, which enables surgeons to verify safe positioning against the bone while ensuring the nerve is adequately protected. Additionally, it features the MicroBlade Shaver, an instrument for removing impinging bone and ligament, along with essential accessories such as guidewires, probes, and distal handles.

TriVascular

Series A in 2008
TriVascular Technologies, Inc. is a medical device company focused on developing and commercializing innovative technologies for the minimally invasive treatment of abdominal aortic aneurysms (AAA) and thoracic aortic aneurysms (TAA). Based in Santa Rosa, California, TriVascular specializes in endovascular grafts and self-expanding stent grafts, including the Ovation and Ovation Prime Stent Grafts, which utilize polymer-filled sealing rings to enhance procedural efficacy. The company’s products are designed to improve patient outcomes by reducing mortality, morbidity, and costs associated with traditional open surgical repair. TriVascular markets its technologies through direct sales in the United States and select European countries, as well as through distributors in other regions. Founded in 2007, TriVascular operates as a subsidiary of Endologix Inc. and emphasizes addressing unmet clinical needs while fostering a supportive work environment for its employees.

ViewRay

Series B in 2008
ViewRay, Inc. is a medical technology company that specializes in designing, manufacturing, and marketing advanced radiation therapy systems for cancer treatment. Its flagship product, MRIdian, is a magnetic resonance image-guided radiation therapy system that simultaneously images and treats cancer patients. By integrating MRI technology with radiation delivery and proprietary software, MRIdian enhances the precision of radiation therapy. It can accurately locate and target soft-tissue tumors while minimizing exposure to surrounding healthy tissue. This capability allows clinicians to treat patients who might not have been suitable candidates for traditional radiation therapy, ultimately leading to improved safety and effectiveness in treatment outcomes. Headquartered in Oakwood, Ohio, ViewRay serves a diverse range of healthcare institutions, including university research hospitals, community hospitals, and freestanding cancer centers, and operates both domestically and internationally. The company was founded in 2004.

CVRx

Series D in 2007
CVRx, Inc. is a medical device company headquartered in Minneapolis, Minnesota, that specializes in the development of implantable technologies for the treatment of high blood pressure and heart failure. Founded in 2000, the company has created Barostim NEO, a neuro-modulation therapy that activates the body's natural mechanisms to regulate blood pressure and address heart failure progression. This therapy utilizes an implantable system that is tailored to the individual needs of patients. CVRx also offers the Rheos platform, which includes an implantable pulse generator and carotid sinus leads designed to deliver therapeutic energy to the carotid arteries. With a focus on minimally invasive solutions, CVRx primarily serves patients and healthcare professionals in the United States and internationally, including markets in the United Kingdom, the Netherlands, Italy, and Germany.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.